Abattis Announces Definitive Agreement with Animo Wellness Corporation

Abattis Announces Definitive Agreement with Animo Wellness Corporation

ID: 124135

(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 03/13/12 -- Abattis Biologix Corporation (the "Company" or "Abattis") (CNSX: FLU), is pleased to announce that further to its news release of February 21, 2012, the Company has entered into a share exchange agreement (the "Agreement") with Animo Wellness Corporation ("Animo") and its shareholders for the Company's acquisition of 100% of the outstanding shares of Animo (the "Transaction").

Pursuant to the Agreement, the Company is acquiring all of the issued and outstanding shares of Animo in consideration for which the Company (i) will issue to the shareholders of Animo an aggregate of 500,000 common shares of the Company (the "Payment Shares") at a deemed price of $0.07 per share; and (ii) will pay the shareholders of Animo an aggregate of $25,000.

The closing of this transaction is anticipated to occur by or before March 31, 2012.

About Animo

Animo is a privately held company which holds 75 natural health product licenses "NPNs" issued by Health Canada. Its portfolio of these products ranges from A- Aloe Vera to Z- Zinc.

About Abattis Biologix Corporation

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The company has identified targeted channels to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

Mike Withrow, Director

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Hamza Thindal Capital Corp.
888.371.9098
888.371.9099 (FAX)



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia NuPathe to Report Fourth Quarter and Full Year 2011 Results and Hold Conference Call on Tuesday, March 20, 2012
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 13.03.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 124135
Anzahl Zeichen: 0

contact information:
Town:

VANCOUVER, BRITISH COLUMBIA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 201 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Abattis Announces Definitive Agreement with Animo Wellness Corporation"
steht unter der journalistisch-redaktionellen Verantwortung von

Abattis Biologix Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Abattis Biologix Corporation



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z